LONDON (Reuters) - The University of Oxford’s Brazilian trial of its vaccine candidate will continue after the death of a volunteer, the university said on Wednesday, adding an independent review had revealed no safety concerns.
“Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial and the independent review in addition to the Brazilian regulator have recommended that the trial should continue,” a spokesman for the university said in a statement.
The vaccine has been licenced to AstraZeneca AZN.L.
Reporting by Alistair Smout; Editing by Chris Reese
Our Standards: The Thomson Reuters Trust Principles.